RxDoctor Payments DataLook up a doctor →

Carol Redillas, MD

Neurology · Chalmette, LANPI 1629023908

Payments from drug & device makers

$1,308,456in general payments, 2019–2025

Across 1,183 payments — averaging $1106.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$524K
  • Biohaven Pharmaceutical Holding Company Ltd.$302K
  • Pfizer$103K
  • Ipsen Innovation$96K
  • Lilly USA, LLC$67K
  • AbbVie$58K
  • plus $160K from 35 others
$261,479in research payments, 2019–2025

Across 6 payments — averaging $43,580 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$261K
  • Ipsen Innovation$419

What the payments were for

  • Consulting fees$13,8157%
  • Speaking & faculty fees$146,92376%
  • Grants$440%
  • Travel & lodging$10,1055%
  • Food & beverage$21,11911%
  • Education$1680%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,308,456 in reported general payments places this provider in the 95th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$96,828
Medicare patients
72
Services billed
9,816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyeptiEptinezumab-Jjmr28$98,319
UbrelvyUbrogepant66$88,882
QuliptaAtogepant54$60,153
Nurtec OdtRimegepant Sulfate37$58,152
BotoxOnabotulinumtoxina45$56,529
Aimovig AutoinjectorErenumab-Aooe44$38,049
XcopriCenobamate21$37,888
Emgality PenGalcanezumab-Gnlm41$29,303
Emgality SyringeGalcanezumab-Gnlm14$23,705
ReyvowLasmiditan Succinate18$21,131
Ajovy AutoinjectorFremanezumab-Vfrm24$19,531
Butorphanol Tartrate105$6,414
Ergotamine-CaffeineErgotamine Tartrate/Caffeine14$5,800
Sumatriptan Succinate144$5,345
Topiramate115$3,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$58,048$205,564165 claims
Lundbeck LLCVyepti$1,240$98,31928 claims
PfizerNurtec Odt$102,835$58,15237 claims
SK Life Science, Inc.Xcopri$22,210$37,88821 claims
Lilly USA, LLCReyvow$66,786$21,13118 claims
Upsher-smith Laboratories LLCTopiramate$625$3,248115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 neurology providers in Louisiana.

Other neurology in Chalmette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →